What is Tesamorelin?
An introduction to tesamorelin (Egrifta), the FDA-approved GHRH analog for HIV lipodystrophy. Learn how it works and its specific medical applications.
What is Tesamorelin?
Tesamorelin (brand name Egrifta) is an FDA-approved medication that stimulates the body’s natural growth hormone release. It’s specifically approved for reducing excess belly fat in people with HIV.
Key Facts
| Fact | Detail |
|---|---|
| FDA Approved | Yes (2010) |
| Brand Name | Egrifta, Egrifta SV |
| Indication | HIV-associated lipodystrophy |
How Does It Work?
Tesamorelin is a GHRH (growth hormone-releasing hormone) analog. It tells the pituitary gland to release growth hormone naturally, which then helps reduce visceral (belly) fat.
What Is It Used For?
Approved Use
Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (abnormal fat distribution caused by HIV medications).
Not Approved For
- General weight loss
- Anti-aging
- Athletic performance
- Non-HIV related conditions
Administration
- Daily subcutaneous injection
- Self-administered at home
- Requires prescription and monitoring
Common Side Effects
- Injection site reactions
- Joint pain
- Swelling (fluid retention)
- Numbness/tingling
This guide is for educational purposes only. Tesamorelin requires a prescription and is for specific medical conditions.
Sources & Citations
- 3journalTesamorelin: a review of its use in the management of HIV-associated lipodystrophy
pmid-21668043
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.